Tandem Diabetes Care (TNDM) Net Income towards Common Stockholders (2013 - 2026)

Tandem Diabetes Care (TNDM) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$20.4 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 84.38% year-over-year to -$20.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$94.5 million (up 48.59% YoY) and the FY2025 annual result came in at -$204.7 million, down 113.18% from the prior year.
• Net Income towards Common Stockholders declined to -$20.4 million in Q1 2026, from -$543000.0 in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $755000.0 in Q4 2024 to a low of -$130.6 million in Q1 2025.
• A 5-year average of -$37.5 million and a median of -$30.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 951.88% — and 2024, when it soared 102.52%.
• Tracing TNDM's Net Income towards Common Stockholders over 5 years: stood at -$15.9 million in 2022, then plunged by 88.58% to -$30.0 million in 2023, then surged by 102.52% to $755000.0 in 2024, then sank by 171.92% to -$543000.0 in 2025, then slumped by 3656.91% to -$20.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$20.4 million (Q1 2026), -$543000.0 (Q4 2025), and -$21.2 million (Q3 2025), per Business Quant data.